NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx" or the "Company") today issued the fo

WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S

D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TM

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a

Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100

NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise cap

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to

Key highlights from the first quarter of operations under the expanded management team include the f

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 pe

NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, w

Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial M

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic th

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP)

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

In the Order, the President notes that, "It is the policy of my Administration to accelerate inn

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on l

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 p

The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism ar

NRXP has received confirmatory minutes from an in-person Type C guidance meeting at the headquarters

Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation

HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) w

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no a

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a